ReShape taps Allergan vet Bandy for CEO | Personnel Moves, April 3 2019

ReShape LifesciencesReShape Lifesciences (NSDQ:RSLS) said last week that it named Allergan (NYSE: AGN) veteran Barton Bandy to replace Dan Gladney in the corner office, effective April 1.

Gladney, who announced his retirement in January, is staying on as chairman. Bandy spent a decade at Inamed until its $3.2 billion purchase by Allergan in 2005.

“I am very pleased to welcome Bart to the ReShape team. His experience and success – particularly with the Lap-Band business at Inamed and Allergan – in addition to his leadership track record since then make Bart the perfect next leader for ReShape,” Gladney said in prepared remarks. “I would like to thank the ReShape team for the hard work and dedication during my time as CEO and I look forward to assisting in a smooth transition and continuing on as a dedicated chairman of the board.”

“This is a very exciting time to be joining ReShape. My experience leading and building medical device organizations and the company’s strategic shift to the proven Lap-Band product, which I know very well, present immediate growth opportunities,” Bandy added. “It is also an incredibly exciting time to see the next-generation, revolutionary ReShape Vest through clinical studies to commercialization. I am thrilled to be part of ReShape Lifesciences and to help drive its future success.”

 Alcon lures HP CFO Stonesifer as finance chief
Novartis (NYSE:NVS) eye business Alcon said it lured Hewlett Packard HPE CFO Timothy Stonesifer to be its new CFO ahead of Alcon’s April 9 spinout.

Current CFO David Murray “decided for family reasons to return to Europe and remain with Novartis,” the company said.

“Tim joins us at an exciting time as we become an independent organization and the world’s leading eye care device company,” Alcon CEO David Endicott said. “He is an outstanding addition to our leadership team, bringing extraordinary financial acumen and deep experience in capital markets transactions, having served as CFO for numerous companies. Tim is also respected in the financial community and known for his ability to develop top-performing finance organizations that deliver results.”

“I am excited to join the exceptional team at Alcon,” Stonesifer added. “For more than 70 years, Alcon has been synonymous with eye care. We share a passion for serving customers and a vision for delivering innovative products that will continue to shape the industry while driving profitable growth.”
Read more

 Exsomed names Maya as CEO
ExsoMed said it named former Tenex Health CEO Bill Maya as its new chief executive effective March 16. Interim CEO Jon Holder moved to the chief revenue officer slot, the company said.
Read more

 iCad promotes Stevens to president
iCad (NSDQ:ICAD) said it promoted its strategy & commercial chief, Stacey Stevens, to president.
Read more

 Ex-J&J litigation head is Stryker’s new chief legal officer
Stryker (NYSE:SYK) tapped the worldwide litigation head at Johnson & Johnson (NYSE:JNJ), Rob Fletcher, to be its new chief legal officer following the April 22 departure of Michael Hutchinson, who is slated to move to VP & advisor to CEO Kevin Lobo.
Read more

J&J’s DePuy Synthes goes after Orthofix, ex-reps in poaching lawsuit

DePuy Synthes, OrthofixJohnson & Johnson (NYSE:JNJ) unit DePuy Synthes last week sued Orthofix (NSDQ:OFIX) and a pair of former DePuy sales reps, alleging that its rival lured the reps and two other colleagues away so it could poach DePuy clients in Alabama and Texas.

According to the suit, filed in the U.S. District Court for Eastern Texas, DePuy hired Thomas Wells and Michael Sewell in 2012 as sales consultants for DePuy Synthes for the territory around Dothan, Ala. After the duo quit in March 2017 within hours of each other, the suit alleged, routine inventory checks at one of their clients revealed Orthofix devices and instruments that were sterilized and ready for surgery at on of their DePuy clients, Southeast Alabama Medical Center.

“In other words, Orthofix equipment had been brought in and was ready to be used in surgery,” according to the suit. And although DePuy products were slated to be used in multiple procedures that week, all but one of those cases were canceled.

“Despite its best efforts, DePuy Synthes has not done any further business at SEAMC,” according to the March 22 lawsuit. “Orthofix was able to convert an account worth millions of dollars practically overnight by using the investments DePuy Synthes made its customers relationships, goodwill, specialized training, and confidential information through Messrs. Wells and Sewell, inducing them to leverage these investments to Orthofix’s benefit.”

The lawsuit does not name Wells and Sewell as defendants, but two other sales consultants in its Longview, Texas, sales region were named in the suit. DePuy accused Orthofix of targeting Scott Mackey and Miranda Middleton in late 2017, alleging that they accompanied “key DePuy Synthes’ surgeon customers to visit Orthofix’s headquarters in Lewisville, Texas,” a month before their “abrupt and simultaneous resignations.”

“Mackey and Middleton encouraged and aided each other in deciding to leave DePuy Synthes and join Orthofix and assisted each other in executing a simultaneous resignation from DePuy Synthes,” the suit alleged. “DePuy Synthes learned shortly after their resignations, but while they were still employed with DePuy Synthes, that Mackey and Middleton started to make arrangements to have Orthofix equipment available at their accounts while they were still employed with DePuy Synthes.”

The lawsuit seeks actual and compensatory damages, disgorgement of all profits generated by Wells Sewell, Mackey and Middleton, legal costs and interest.

The post J&J’s DePuy Synthes goes after Orthofix, ex-reps in poaching lawsuit appeared first on MassDevice.

Nevro taps ex-Thoratec CEO Grossman | Personnel Moves, March 20, 2019

Nevro taps ex-Thoratec CEO GrossmanNevro Corp. (NYSE:NVRO) said yesterday that it named former Thoratec CEO Keith Grossman to replace president & CEO Rami Elghandour after striking a deal with one of its investors, Broadfin Capital.

Grossman re-joined Thoratec after taking over at Conceptus in December 2011 and leading it to a $1.1 billion sale to Bayer in June 2013 (he’d been Thoratec’s CEO from 1996-2006). Grossman helmed Thoratec until St. Jude Medical (now Abbott) acquired it in October 2015 for $3.3 billion.

Nevro said the deal with Broadfin also involves the expansion of its board of directors with the addition of Warburg Pincus limited partner Bess Weatherman and medtech veteran Kevin O’Boyle and the departure of director Ali Behbahani. Broadfin picked up a 5.8% stake in Nevro in September 2015 but cut that to less than 0.2% in February 2017, according to regulatory filings.

“On behalf of the board and our entire company, I am excited to welcome Keith Grossman to the Nevro team,” chairman Michael DeMane said in prepared remarks. “Keith brings over 30 years of experience in leading innovative medical technology companies through periods of strategic change to deliver growth and enhanced value for stockholders. As we look to the future, I am confident that under Keith’s direction, Nevro will be well positioned to capture a burgeoning market opportunity with its pioneering spinal cord stimulation (SCS) technology to treat chronic pain.”

“I am excited by this opportunity to join such a talented team at a pivotal moment in Nevro’s history,” Grossman added. “Over the past several years, Nevro has leveraged the strength of its technology to enhance patient care and drive overall industry growth. Nevro is now at an inflection point, and I am confident in our ability to continue delivering value not only to our patients and customers, but importantly, to our stockholders. I look forward to working closely with the board and the full Nevro team to advance the company into its next phase of growth.”

Broadfin also agreed to back Nevro’s board nominees at its next shareholders meeting and to obey standstill provisions and voting commitments. Nevro said it’s suspending its revenue guidance pending Grossman’s assessment.

NVRO shares were up 25.0% to $55.96 apiece today in pre-market trading ahead of a $44.51-per-share open and jumped 33.8% to $59.91 shortly thereafter.

 Synaptive Medical names Clarke as CFO
Synaptive Medical said it named Sandra Clarke as its new finance chief.

“Ms. Clarke is an incredible addition to our team,” CEO Peter Wehrly said in prepared remarks. “With her accomplished background and experience working for companies at critical inflection points, Ms. Clarke will play a key role at Synaptive as we continue expanding our presence globally.”

“I’m very excited to join Synaptive and work closely with the team to continue advancing their efforts in transforming neurosurgical technologies,” Clarke added. “Given the increasing need for advanced neurological care, I’m pleased to be working for a company that is committed to providing physicians the tools necessary to achieve optimal patient outcomes.”
Read More

 ElectroCore CFO Vraniak taps out, Posner taps in
ElectroCore CFO Glenn Vraniak is resigning effective April 1 and is to be replaced by Cellectar Biosciences finance chief Brian Posner.
Read More

 Rosenzweig joins Check-Cap as CFO
Check-Cap (NSDQ:CHEK) said it appointed former Entera Bio (NSDQ:ENTX) CFO Mira Rosenzweig as its own finance chief, effective April 28.
Read More

 Ex-K2M CIO Staubach lands at Tactile Medical
The new chief information officer at Tactile Systems Technology (NSDQ:TCMD) is ex-K2M CIO Peter Schaubach.
Read More

The post Nevro taps ex-Thoratec CEO Grossman | Personnel Moves, March 20, 2019 appeared first on MassDevice.

Cantel Medical taps ex-Cardinal Health COO Fotiades for CEO | Personnel Moves, March 5, 2019

Cantel Medical CEO Fotiades Cantel Medical taps ex-Cardinal Health vet for CEO
Cantel Medical (NYSE:CMD) said today that it named former Cardinal Health (NYSE:CAH) COO George Fotiades to be its new president & CEO, replacing Jorgen Hansen effective immediately. Fotiades will retain his seat on Cantel’s board, the Little Falls, N.J.-based company said.

“On behalf of the board, I am very pleased to appoint George as Cantel’s new president & CEO. His experience leading companies through significant growth, creating organizational capabilities on a global scale and integrating acquired businesses make him the ideal candidate to lead Cantel at this juncture. George has been a key contributor to the board for over a decade and will make a seamless transition to this role. The board and I look forward to working with George in his new capacity to support the next phase of Cantel’s development,” chairman Charles Diker said in prepared remarks. “We thank Jorgen for his many contributions to Cantel. During Jorgen’s tenure, Cantel made significant progress expanding internationally and completed a number of key strategic acquisitions that have bolstered our market position and driven growth. Jorgen is a talented executive of the highest integrity and we wish him all the best in the next phase of his career.”

“It has been a privilege to lead the team at Cantel. During my tenure, we executed on our ambitious strategy, strengthening Cantel’s business and global reach. By doing so, we have taken the company’s mission of saving lives through infection prevention to the next level. I am proud of what we have accomplished together,” Hansen aded.

“Cantel has an excellent market position and many opportunities ahead for both organic growth and continued acquisition activity,” Fotiades said. “I look forward to working with the board and the executive leadership team in my new role to improve our operating model and performance, drive organic growth, attract and cultivate top leadership talent and identify attractive acquisition candidates and expansion opportunities.”

Cantel took a hit last week when it missed the consensus forecast with its fiscal second-quarter results. Read More

 Activ Surgical’s first CEO is ex-Olympus medical systems prez Usen
Activ Surgical said it named Todd Usen, the former president of Olympus Medical Systems, to be its first CEO. Activ is developing the Smart Tissue Autonomous Robot for imaging and diagnostics during robot-assisted surgeries.

“I’m incredibly thrilled to have Todd join and lead the Activ Surgical team. Todd’s outstanding experience and leadership in the endoscopic space provides a natural synergy to Activ’s disruptive vision of delivering enhanced surgical vision and intelligence,” co-fopunder and chief scientific officer Dr. Peter Kim said in prepared remarks.

“It’s a tremendous privilege to be selected to lead Activ Surgical as its first CEO,” Usen added. “I look forward to working with our board, advisors and Activ Surgical team to realize the full potential of our unique and proprietary technology.”

Usen is also an eight-year veteran of Smith & Nephew (NYSE:SNN), where he held roles including U.S. orthopedics president, and Boston Scientific (NYSE:BSX). Read More

 Globus Medical president Williams bows out
Globus Medical (NYSE:GMED) said president Anthony Williams gave notice Feb 28 of his plans to “pursue opportunities outside of the company,” with his last day slated to be May 31 “to ensure a seamless transition.” CEO Dave Demski is due to take over the Audubon, Pa.-based company’s presidential duties after that. Read More

 BioDirection puts Joshi in the corner office
Concussion and traumatic brain injury device maker BioDirection said it named Sharad Joshi as president & CEO.
Read More

 CathWorks names Feher as CFO
CathWorks named Edwards Lifesciences (NYSE:EW) vet Mike Feher as CFO and finance VP. Last month Cathworks closed a $30 million Series C round for its FFRangio fractional flow reserve device. Read More

The post Cantel Medical taps ex-Cardinal Health COO Fotiades for CEO | Personnel Moves, March 5, 2019 appeared first on MassDevice.

Orthofix slumps on top-line misses, CEO Mason to retire

OrthoFixOrthofix (NSDQ:OFIX) missed the consensus for its fourth-quarter and 2018 sales, sending its share price down by double digits today in mid-afternoon trading despite a huge bottom-line gain.

Lewisville, Texas-based Orthofix reported profits were up 465.8% to $8.9 million, or 46¢ per share, on sales growth of 3.6% to $121.1 million compared with Q4 2017. Adjusted to exclude one-time items, earnings per share were 55¢, 7¢ ahead of the consensus on Wall Street; however, analysts there were looking for sales of $121.5 million.

“With the recent FDA approval of the M6-C artificial cervical disc, the primary focus in our spine business is on the launch in the U.S., which we expect will happen late in the second quarter,” said president & CEO Brad Mason, who also announced plans to retire. “This approval is an important milestone in our transition to a top-line growth story beginning in the second half of this year and accelerating in 2020.

“What I’ve always done best and enjoyed the most in my career is starting and fixing companies. I love the challenges associated with these phases in a business’s lifecycle,” Mason added. “Now with the stage set for the company’s next chapter, I’ve finished what I came to do. Because of the tireless efforts of the talented and dedicated Orthofix team, we’ve accomplished everything and more than I ever expected. Therefore, I believe it is the right time for both the company and for me to pass the reins to a new leader who will take Orthofix through the next chapter and capitalize on this enormous potential.”

Orthofix said Mason plans to stay on until a replacement is found and consult thereafter. The company forecast adjusted 2019 EPS of $1.75 to $1.82 on sales of $472.0 million to $477.0 million.

OFIX shares were off +12.5% to $59.25 apiece today in mid-afternoon activity.

The post Orthofix slumps on top-line misses, CEO Mason to retire appeared first on MassDevice.

Abiomed wants whistleblower to cough up employment records

AbiomedAbiomed (NSDQ:ABMD) yesterday asked a federal judge to force whistleblower Max Bennett to cough up his employment records with another company, countering his retaliatory termination claim by alleging that it fired him for lying about the circumstances of his departure from his last job.

Documents unsealed in March 2018 revealed that Max Bennett accused the Danvers, Mass.-based heart pump maker of firing him in retaliation for accusing it of a kickbacks scheme involving the wining and dining of physicians at fancy restaurants to encourage them to use its Impella pump, according to court documents. Abiomed agreed that month to pay $3.1 million to settle the whistleblower case with the U.S. Justice Dept.; Bennett was due $542,000 from the settlement, the Justice Dept. said at the time.

Now Abiomed alleges that Bennett lied about being fired from Biotronik and wants the court to force him to produce his employment records to prove it. Bennett declined to produce the documents during discovery, arguing that they are barred under a nondisclosure agreement and are irrelevant to boot, according to the documents.

“Abiomed’s primary defense to plaintiff’s claims is that plaintiff was terminated because of his dishonesty during the interview process about the circumstances of his separation from Biotronik, not because of any alleged complaints he made,” the company argued. “Abiomed also believes that any complaints that Plaintiff made after he was confronted regarding his apparent false representations regarding the circumstances of his separation from Biotronik were not made in good faith.” [emphasis theirs]

During the interview process ahead of his October 2012 hiring, Bennett told Abiomed that he left Biotronik after the cardiac rhythm management company changed its sales model.

“In 2010, I left Biotronik due to changes in the business model. Biotronik chose to pursue an independent model vs. a direct model, which in turn minimized the functional need for management positions. I signed a non-disclosure and took a severance option at that time. Given my entrepreneurial personality and strong network in the industry, I decided to try my own consulting,” Bennett wrote in an email filed with Abiomed’s motion to compel.

The requested documents are critical to its case, the company argued, “because they will show that plaintiff was, in fact, terminated from Biotronik, in direct contradiction to statements he made to Abiomed during the interview process that his separation from Biotronik was voluntary.

“Abiomed understands that plaintiff is concerned that production of the requested documents would breach a confidentiality provision set forth in an agreement he entered with Biotronik. However, counsel also understands that the Biotronik agreement provides that it will not be a violation of the confidentiality provision if production is made pursuant to a court order. Given this, any such concern will be resolved by an order of this court,” Abiomed argued in the Jan. 9 motion.

Earlier this week the company won another lawsuit brought by a former employee, who alleged unfair termination and the denial of an options deal tied to Japanese approval for Impella.

The post Abiomed wants whistleblower to cough up employment records appeared first on MassDevice.

Philips rejiggers, promotes image-guided therapies head van Meurs

PhilipsRoyal Philips (NYSE:PHG) said today that it’s rejiggering its corporate structure and promoting the head of its image-guided therapies business to its executive committee.

The Dutch healthcare giant said the changes include shifting sleep & respiratory from the personal health segment to the new connected care division and moving healthcare informatics into the diagnosis & treatment segment.

Under the new structure Philips has thee divisions, effective Jan. 1:

  1. The diagnosis & treatment business, including diagnostic imaging, ultrasound and healthcare informatics, is led by Rob Cascella. Bert van Meurs, newly elevated to the executive committee, leads the image-guided therapy business under the Dx & treatment umbrella.
  2. The connected care business now includes monitoring & analytics, therapeutic care, population health management and sleep & respiratory care, led by Carla Kriwet.
  3. The personal health segment includes personal care, domestic appliances, oral healthcare and mother & child care and is led by Roy Jakobs.

“The appointment of Bert van Meurs as a new member of the executive committee reflects the growth of our image-guided therapy businesses,” CEO Frans van Houten said in prepared remarks. “To strengthen our leadership in this fast-growing market, we have significantly invested in our R&D programs which resulted in the launch of the very successful Azurion next-generation image-guided therapy platform, and the acquisitions of Volcano, Spectranetics and most recently EPD Solutions, which enabled the expansion into smart devices such as diagnostic and therapeutic catheters.”

Philips also reinforced its guidance for 2017 to 2020, saying it still expects to log 4% to 6% comparable sales growth and add 100 basis points to its adjusted EBITA margin. The company also doubled down on its pledge to improve organic return on invested capital to mid-to-high-teens levels in 2020. The target for annual free cash flow is more than €1.5 billion in 2020, Philips said.

The company plans to release its full fourth-quarter and 2018 results Jan. 29.

PHG shares, which closed up 3.0% at $35.47 apiece yesterday in New York, were off -0.8% to $35.19 each in pre-market trading today.

The post Philips rejiggers, promotes image-guided therapies head van Meurs appeared first on MassDevice.

Ex-Abiomed exec loses $2m lawsuit


A former Abiomed (NSDQ:ABMD) Asia VP lost a lawsuit that sought $2.1 million in damages, alleging unfair termination and the denial of an options deal tied to Japanese approval of its Impella heart pump.

The Danvers, Mass.-based heart pump maker hired the plaintiff, Keisuke Suzuki, in 2010 to help it pursue Japanese regulatory approval for the Impella device. Their agreement included a provision that would give Suzuki 45,000 ABMD shares pegged to Japanese regulatory milestones.

Suzuki claimed that Abiomed was resistant to his suggestions and recommendations for winning approval from the Japanese Ministry of Health, Labour & Welfare and Japan’s Pharmaceutical & Medical Device Agency, unnecessarily prolonging the process. Abiomed was on target to achieve approval of the devices in 2015, having met with Japan’s PMDA and established guidelines for what was necessary for the clearance, Suzuki alleged, according to court documents.

After the PMDA meetings, he claimed, the company began to give him false negative job performance reviews, sought to demote him and to “change the terms of his compensation so as to take away his stock rights and future commission rights,” according to the documents.

The lawsuit alleged that Abiomed fired him without the 28-day notice required by his contract and denied him the 20,000 ABMD shares he was allegedly due based on Japanese approval of the Impella line. Suzuki sought damages for the alleged retaliation, lost wages and the price of the shares.

Abiomed denied all of Suzuki’s claims and alleged instead that it took another 15 months after Suzuki’s firing to win Japanese approval for Impella. The company asked for summary judgment from Judge Denise Casper of the U.S. District Court for Massachusetts, who last week granted the motion.

“Given that Suzuki was not due compensation for a milestone that was not achieved at the time of his termination and was not achieved until 15 months later after considerable additional effort by Abiomed, such that it cannot be reasonably concluded that he was ‘on the brink’ of reaching this milestone, Abiomed’s termination of Suzuki does not amount to bad faith or violation of the implied covenant of good faith and fair dealing,” Casper ruled Jan.4, according to the documents.

The post Ex-Abiomed exec loses $2m lawsuit appeared first on MassDevice.

Former Rotation Medical CEO Shadan joines Miach Ortho | Personnel Moves – January 3, 2019

Miach Orthopaedics CEO Martha ShadanEarly stage medtech firm Miach Orthopaedics said today that it named former Rotation Medical CEO and medtech vet Martha Shadan as its new prez and chief executive officer.

Shadan has held numerous leadership positions at medtech firms, including Zimmer Biomet (NYSE:ZBH), Covidien, Bristol Myers Squibb and Merck, Westborough, Mass.-based Miach said. Prior to joining Miach, Shadan lead rotator cup repair device firm Rotation Medical, which was acquired by Smith & Nephew for $210 million in December 2017.

Shadan has also served as exec chairwoman of Miach’s board of directors since September last year, the company said. She also serves on AdvaMed’s board of directors, and serves as board chair of the Accel Board of Directors and is a founding member of the Leadership Circle for the Women’s Executive Network.

“We are very glad to have Martha Shadan joining the Miach team. Her experience in the medical device space with successful commercialization of medical devices brings in a very valuable skill set, and we are very much looking forward to working with her as the CEO,” founder & chief medical officer Dr. Martha Murray said in a press release.

 NuVasive’s new CEO Barry shuffles the deck

NuVasive (NSDQ:NUVA) said today that its new CEO and former Medtronic (NYSE:MDT) surgical innovations prez Chris Barry has made significant organizational changes to its executive leadership roster as the company looks to improve internal growth and drive innovation.

The San Diego-based company said that its current prez Matt Link will retain his position with expanded responsibilities, including the direct management of its clinical services and global logistics businesses.

Current CFO and exec VP Raj Asarpota will retain their role alongside new responsibilities leading the company’s finance, accounting, internal audit and tax teams, the company said, while GC and corporate secretary Nate Sisitsky will continue in their role, but will also oversee the company’s real estate and facilities.

Chief compliance officer Jim Garrett will assume an expanded role overseeing the company’s business and quality systems functions, which includes GRI, regulatory affairs and quality affairs, information technology and environmental health and safety, NuVasive said.

Former HR VP Lucas Vitale was named chief human resources officer, while internal and external affairs lead Suzanne Hatcher and manufacturing head Dale Wolf will retain their positions, the company said.

The positions of global process transformation and people and culture exec VP, held by Stephen Rozow and Pete Leddy, respevtively, have been eliminated, NuVasive said.

“After assessing the company over the past two months as CEO, it is clear that NuVasive benefits from significant talent across the organization. Our new structure will enable us to better capitalize on this talent by fostering cross-functional collaboration, consolidating complementary functions and increasing accountability. I am confident this leadership team and our new structure, along with disciplined execution, will better position NuVasive to fulfill our commitments to patients, surgeons, employees and shareholders, and drive NuVasive’s success and sustainable growth,” Barry said in a press release.

Read more

 Obalon Therapeutics promotes prez, COO Huang to the corner office

Obalon Therapeutics (NSDQ:OBLN) said yesterday that it promoted former prez & chief operating officer Kelly Huang to the position of chief executive officer, with former CEO Andy Rasdal taking up the position of exec chair.

Prior to joining Obalon, Huang served as GM for Galderma Laboratories’ aesthetic & corrective division. Before taking the position with Galderma, Huang acted as prez of Endo Pharmaceutical’s exec committee, San Diego-based Obalon said.

“More than a year ago, we brought Kelly in as chief operating officer to lead commercial operations. Kelly has continued to demonstrate that he is a strong and capable leader, and we believe he will be effective as CEO of Obalon. I intend to stay actively involved as executive chairman, primarily to serve as a resource to Kelly, and will also focus on several key strategic projects to help build the intragastric balloon market and create sustainable value for Obalon,” Rasdal said in a press release.

The company also announced that it promoted its clinical and regulatory affairs VP Amy Vandenberg to the position of chief clinical and regulatory affairs officer. Prior to joining Obalon, she held positions at companies including Dexcom and Cygnus.

“Amy led the clinical and regulatory aspects for FDA approval of Obalon’s original PMA and recent PMA-S approval of the Navigation/Touch system.  She continues to lead across all functions and levels of the organization.  I am pleased to recognize Amy’s contributions to the current business and future pipeline with her promotion to chief clinical & regulatory affairs officer,” CEO Huang said in a separate release.

Read more

 Lightmed lifts founder & exec chair Lee to the corner office

Lightmed said yesterday that it reappointed its founder and exec chair Gary Lee as its new CEO, replacing Shlomo Alkalay who will return to a consultancy position.

In addition to the appointment, the San Clemente, Calif.-based company said that biz dev director Jennifer Lee was appointed to GM of Americas, effective immediately.

“I am proud to say that during my 1.5 years as CEO of Lightmed, the company has successfully accomplished implementation of our turn-around plan. Lightmed is now much better equipped with best-of-breed automated processes, controls and KPIs to face future global challenges and meaningful growth. I’ve completed what I set out to do and feel confident the company is not only in great shape, but I’m leaving it in the strongest hands under the original leadership of the company founder, Gary Lee,” Alkalay said in a prepared statement.

“Shlomo has shown exceptional leadership and has strategically guided Lightmed to a better position. Speaking on behalf of the entire board, we very much appreciate Shlomo’s service to Lightmed and he will be missed. Shlomo joined as CEO just at the right time when I needed to focus my efforts on our venture capital strategy. Now that the company is healthier and running smoothly, I’m looking forward to taking Lightmed to the next level of expanded product innovation and growth. Furthermore, I’m excited that our director of business development, Jennifer Lee, has assumed her new role in managing the USA, Latin America and Canada. Jennifer is an excellent leader and communicator who has shown remarkable capabilities in building new and existing business relationships. I look forward to seeing her grow our western market in 2019,” Lee said in a prepared release.

Read more

 Nobilis Health taps Springfield as CEO

Nobilis Health said late last month that it appointed James Springfield as its new CEO.

Prior to joining Houston-based Nobilis, Springfield held positions with Memorial Hermann Health Care System, and served in leadership positions at a number of different hospitals and health systems.

“I am excited to take on this role and opportunity, as I have followed the Nobilis story in the Texas market and have seen their dramatic shift in-network and how the management team has successfully grown its medical facility infrastructure (including clinics, ambulatory surgery centers, and hospitals) as well its unique direct to consumer marketing platform.  This proprietary marketing technology provides Nobilis with the unique ability to quickly add new products and specialties and in combination with the recent significant increase of the company’s in-network business, makes Nobilis poised for strong and sustainable growth.  The scalability of the marketing platform allows Nobilis to enter new markets with ease and certainty. With the significant expansion of the company’s in-network business, there is now an opportunity to recruit from a much larger base of physicians, especially in the Texas market. The company intends to pursue alignment with physicians in new and existing specialties, while expanding the Nobilis brands to include total joint replacements, ENT and cardiovascular services, among others.  This is a vision and strategy that the management team and the company’s board of directors share. As Nobilis’ CEO, I welcome the responsibility of executing on this vision, and look forward to achieving the results I believe shareholders want to see. Nobilis will be the only in-network healthcare system that can use marketing to address both patient and provider needs.  In the coming months I look forward to sharing a clear plan on maximizing shareholder value for Nobilis investors,” Springfield said in a press release.

“Jim has extensive executive leadership experience with several of the nation’s largest healthcare providers and payors which fits in well with Nobilis’ shift to an in-network system. The addition of Jim Springfield to the Nobilis team as CEO will allow us to execute and achieve the benefits of an in-network model, including faster collection cycle, larger addressable market, certainty in revenue recognition, and greater willingness from physicians to participate in the in-network space, among other key advantages. He has led out of network to in-network conversions and is ideally suited to finalize Nobilis’ migration to being an in-network healthcare provider,” board chair Harry Fleming said in a prepared statement.

Read more

The post Former Rotation Medical CEO Shadan joines Miach Ortho | Personnel Moves – January 3, 2019 appeared first on MassDevice.

FDA names Flatiron Health’s Abernethy as deputy commish | Personnel Moves, December 19, 2018

FDA principal deputy commissioner Amy AbernethyThe FDA this week named Amy Abernethy, the chief medical officer for Roche subsidiary Flatiron Health, as principal deputy commissioner to replace Rachel Sherman, who is retiring in January.

“She’s a highly regarded thought leader who has held numerous positions of leadership in her fields of interest and distinguished herself for her intellect, her passion for patient care and science, and her collegiality,” FDA commissioner Dr. Scott Gottlieb wrote in a staff memo, according to Forbes.

“In my wildest dreams, I wouldn’t have imagined Scott could come up with somebody this highly qualified,” added former commissioner Dr. Robert Califf, who the magazine described as a mentor of Abernethy’s. “So I think it’s really good for the country. I’m really excited about it.”

“I had always thought I would go into government service, and I have always believed that one of the ways you make change is through policy and regulation,” Abernethy said. “The more we have precision medicine the more it means we stop doing things that don’t work.

“This is not my chance to solve the set of problems I think are important,” she says. “It’s a chance to spend 100% of my time solving problems that are important for human health,” she told the magazine.

Abernethy said she would accede to FDA conflict-of-interest rules regarding her role at Flatiron.

“I happen to be a methods expert in data, that is what my expertise is in, full stop. As the issue is how to use data, you would argue that Flatiron is a data company and FDA is a data agency,” she said. “I will follow the rules.”

 Livongo taps ex-Cerner prez Burke as CEO

Livongo Health said it tapped former Cerner (NSDQ:CERN) president Zane Burke as CEO, replacing Glen Tullman, who’s slated to become chairman.

“Zane spent two decades building relationships with the top health systems in the world. He knows the healthcare challenges facing employers, providers, and those with chronic conditions,” Tullman said in prepared remarks. “Livongo is growing rapidly with significant opportunities on the horizon. I believe Zane is the perfect person to take the Company to the next level and to lead Livongo through this period of rapid expansion.”

“With six in ten people living with a chronic condition, the time is right for Livongo’s experiential, fresh approach to improving the quality of life and the health status of people who live with these conditions,” Burke added. “As CEO, my focus will be working with this incredible team to grow the company so that we can create better health and care experiences for our Members, and more appropriately manage the resources consumed in managing those conditions for anyone paying for that care.”

Livongo also said it promoted chief medical officer Dr. Jennifer Schneider to president.

“The opportunity to partner with Jenny and the rest of the Livongo executive team to build on the success Livongo has enjoyed to date is something I’m very much looking forward to,” Burke said in a press release.

“I’m excited about the possibilities in front of us as the leader in applied health signals,” Schneider added. “The marketplace is recognizing our differentiated offering, and we’re now serving more than 600 of the largest, most innovative self-insured employers in the U.S., the two largest pharmacy benefit managers and a growing number of payers and health services organizations. As we rapidly grow our business and build new capabilities, we are able to aggregate and interpret more data on more conditions, and deliver actionable, personalized and timely health signals to more and more people with chronic conditions empowering them get and stay healthy.”

Read more

 iCad makes it official with interim CEO Klein

The board of directors at iCad (NSDQ:ICAD) made it official with interim CEO Michael Klein last week, removing the “interim” from his title.

Read more

 Italian TMVR firm InnovHeart names Bottiglieri as CEO

Milan-based transcatheter mitral valve replacement developer InnovHeart said it named Jason Bottiglieri as CEO, with founder & CEO Giovanni Righini continuing as CTO and director.

Read more

 CLSA names Guerra to succeed Radcliffe as CEO

The California Life Sciences Assn. said yesterday that it appointed Mike Guerra to succeed Sara Radcliffe as president & CEO effective Jan. 7, 2019. Radcliffe is departing to pursue “new opportunities,” the association said.

Read more

The post FDA names Flatiron Health’s Abernethy as deputy commish | Personnel Moves, December 19, 2018 appeared first on MassDevice.